Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4205429 | 1.00 | CTSK (0.49) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL4981261 | 1.00 | CTSK (0.49) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL6684772 | 0.91 | CA1 (0.49) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL9911449 | 0.87 | CA1 (0.52) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL4936593 | 0.86 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL9062184 | 0.86 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1853923 | 0.86 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3908243 | 0.86 | CA1 (0.45) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL344846 | 0.86 | CA1 (0.45) | CTSKCTSSSYKCA1CA2 | |
| SCHEMBL7834317 | 0.86 | CYP2D6 (0.55) | CTSKCTSSSYKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471048-B2 | Ruthenium carbonyl complex having tridentate ligand, its production method and use | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237814-A1 | NOVEL RUTHENIUM CARBONYL COMPLEX HAVING TRIDENTATE LIGAND, ITS PRODUCTION METHOD AND USE | ADH1C, ADH1A, ADH5 | CTSK 3317/4885CTSS 3969/4885SYK 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.